Annandale, VA; September 17, 2020admin4821
The Clinical Alliance for Research and Education – Infectious Diseases (CARE-ID) Opens a New Arm of Vaccine Study
CARE-ID has reached its allocated target for enrollees in its collaboration with Pfizer for clinical research to evaluate the safety and effectiveness of its SARS-CoV-2-RNA vaccine candidate against COVID-19. This is a major CARE-ID milestone in the collaboration and initially this target was thought to be the end goal of its research effort. However, Pfizer has now expanded the original study. The expansion will allow the further increase in trial population diversity, and inclusion of people with chronic, stable HIV (human immunodeficiency viruses), Hepatitis C, or Hepatitis B infection, as well as provide additional safety and efficacy data. In this expansion, Pfizer gains a particularly valuable partner given CARE-ID decades long experience in researching treatments for these particular infectious diseases.